Digital therapeutics meet pharmaceutical expertise: Schwabe invests in NeuroNation

The Schwabe Group has acquired a majority stake in Synaptikon GmbH, the company behind the NeuroNation and NeuroNationMED brands. With this investment, Schwabe is expanding its portfolio of digital health solutions and further strengthening its position in the field of cognitive health.

The Schwabe Group has many years of experience working with medical professionals and offers Tebonin®, an effective herbal medicinal product for mental health. NeuroNationMED complements this approach with a digital application.

Scientifically grounded approach

As demographic change leads to a growing number of people experiencing cognitive decline, the demand for scientifically validated and practical everyday solutions is increasing. This is precisely where Schwabe and Synaptikon share a common vision: both offerings focus on early intervention and support people with similar cognitive health needs.

“We are an excellent strategic and cultural fit,” says Olaf Schwabe, CEO of the Schwabe Group. “Tebonin and NeuroNationMED are based on the same core idea: providing early and practical support for people with cognitive challenges.”

The founders of Synaptikon also view the partnership as an important milestone. “From the very beginning, our vision has been to make effective digital solutions accessible and help people achieve a better quality of life,” says Jakob Futorjanski. “With Schwabe, we are gaining a long-term partner that will support our continued growth,” adds Rojahn Ahmadi.